Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer
Erica Torchiaro, Marco Cortese, Consalvo Petti, Marco Basirico’, Federica Invrea, Alice D’Andrea, Letizia Franco, Dario Sangiolo, Enzo Medico · 2024
Read Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer by Erica Torchiaro, Marco Cortese, Consalvo Petti, Marco Basirico’, Federica Invrea, Alice D’Andrea, Letizia Franco, Dario Sangiolo, Enzo Medico (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11616334.txt.
Description
Erica Torchiaro and co-authors retarget a cell therapy built for other cancers against colorectal cancer, in a 2024 study. Bowel cancer is the third most common cancer worldwide. Many patients never respond to standard drugs or later resist them. CAR cell therapies redirect immune cells at tumor markers. Their harsh side effects push researchers toward natural killer cells instead.
The chosen target, mesothelin, is already common in CAR trials for other tumors. The team armed the NK-92 cell line with the matching receptor. Lab tests checked killing power against bowel cancer cells. The safety profile of killer cells is their main selling point. A positive result widens the CAR map to a major cancer.
Catalog record
| CREATOR | Erica Torchiaro, Marco Cortese, Consalvo Petti, Marco Basirico’, Federica Invrea, Alice D’Andrea, Letizia Franco, Dario Sangiolo, Enzo Medico |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |